About XtalPi
XtalPi is a publicly listed company based in Cambridge (United States) founded in 2014 by Shuhao Wen, Jie Ren, Jian Ma, and Lipeng Lai. AI-driven crystal structure prediction for pharmaceutical development is offered. It operates in the Healthcare and Technology sectors. XtalPi has raised $784.8 million across 7 funding rounds from investors including Google, Tencent and Mirae Asset. The company has 393 employees. XtalPi has completed 1 acquisition, including Liverpool ChiroChem. XtalPi was last valued at $2.01 billion in August 2021. Its website xtalpi.com draws about 28 thousand monthly visits. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is XTALPI INC. Its competitors include Formation Bio, BigHat and Predictive Oncology; 3 of its 3 listed competitors have raised funding.
Company details
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The companys algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
- Headquarters Cambridge, United States
- Employees 393
- Founders Shuhao Wen, Jie Ren, Jian Ma, Lipeng Lai
- Stage Public
- SectorsHealthcareTechnology
- Website xtalpi.com
- Social LinkedIn X
- Legal Name Xtalpi Holdings Limited
- Annual Revenue$111.82 M (USD)201.33as on Dec 31, 2025
- Net Profit$17.24 M (USD)as on Dec 31, 2025
- EBITDA-$49.93 M (USD)44.46as on Dec 31, 2025
- Total Equity Funding$784.8M (USD)
in 7 rounds
- Latest Funding Round$268M (USD), Post-IPO
Sep 2025
- InvestorsGoogle
& 25 more
- Employee Count393
- Investments & Acquisitions
Funding Insights of XtalPi
XtalPi has successfully raised a total of $784.8M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $268 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $784.8M
- Total Rounds 7
- Last Round Post-IPO — $268M
- First Round $3.7M
(Jun 2015)
- Investors Count 26
All 7 funding rounds of XtalPi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $268M | Post-IPO | – | – | – |
| Feb 2025 | $268.4M | Post-IPO | – | – | – |
| Aug 2021 | $400M | Series D | $2.01B | Orbimed | |
| Sep 2020 | $318.8M | Series C | – | SoftBank Vision Fund, People's Insurance Company of China | |
| Oct 2018 | $46M | Series B | – | China Life Investment | |
| Jan 2018 | $15M | Series B | – | HSG | |
| Jun 2015 | $3.7M | Series A | – | Tencent | – |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2021 | $2.01B | •••••••• |
Last known valuation $2.01B (Aug 2021). 26 investors in total: 26 institutional.
Investors in XtalPi
XtalPi has secured backing from 26 investors, including venture fund and institutional investors. Prominent investors backing the company include Google, Tencent and Mirae Asset.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
A venture capital firm focused on technology and innovation investments. | 5ycap.com | Shanghai, China | ||
Venture capital and private equity investments are made across technologies. | hsgcap.com | Hong Kong, China | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Venture capital fund focused on mobile, internet, deep technology, rural internet, AI, and multiple sectors | shunwei.com | Beijing, China | ||
VC firm investing in tech startups across US and China | imo.vc | San Mateo, United States | ||
Private equity investments are managed from bases in China. | chinalifepe.com | Chaoyang, China | ||
Tech companies in China are invested in by SIG China. | sig-china.com | Shanghai, China | ||
| chinalifeinvest.com | ||||
| yaelcapital.com |
Investor details for XtalPi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of XtalPi
33 people are tracked at XtalPi (23 in leadership, 10 in team); the tracked headcount is 393.
| Name | Role | Group |
|---|---|---|
Shuhao Wen | Founder | Leadership |
Jie Ren | Founder | Leadership |
Jian Ma | Founder | Leadership |
Lipeng Lai | Founder | Leadership |
Shigang Ruan | Senior Director | Leadership |
Phoebe Zeng | Head Of Talent Recruitment & HRBP | Leadership |
Ma Jian | Co-Founder & CEO | Leadership |
Yan Ren | Senior Director, Business Development | Leadership |
Bin Chen | Vice President Of Small Molecule AI Drug Discovery | Leadership |
Lai Lipeng | Co-Founder & Chief Innovation Officer | Leadership |
Kevin Tsai | Vice President Of Corporate And Business Development | Leadership |
Chen Zhang | Business Developmemt & Licensing Director | Leadership |
Teng Lin | Senior Vice President, Business Development | Leadership |
Peiyu Zhang | Chief Scientific Officer | Leadership |
Mi He | Director Of Operations | Leadership |
Xinyang Gong | Director, Corporate Finance& Strategy Development | Leadership |
Zihao Hua | Senior Director In Drug Discovery | Leadership |
Lingjian Yang | Bioinformatics Head | Leadership |
Greg Prikler | Senior Director Of Business Development | Leadership |
Kyle Klaassen | Director, Global Business Development - Antibody Discovery | Leadership |
13 more people are available in the full profile.
Complete people profiles for XtalPi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of XtalPi
XtalPi is a publicly listed company on the HKEX with ticker symbol 2228 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Jun 2024
- Listed onHKG: 2228
- Listed entityXtalPi Holdings Limited
- Exchange sectorHealth technology
- ISINKYG7S12M1051
- Share price6.20 HKD (-4.17% on the day) · 2026-10-14
- Market capitalisation27,817,312,335.00 HKD
- EPS (diluted, trailing year)-0.06 HKD
- Volume (last session)53,404,500
Financials of XtalPi
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 870.5M HKD | 134.2M HKD | -388.7M HKD |
| 2024 | 288.9M HKD | -1.64B HKD | -699.8M HKD |
| 2023 | 192.7M HKD | -2.12B HKD | -739.7M HKD |
| 2022 | 155.1M HKD | -1.67B HKD | -546.0M HKD |
| 2021 | 75.7M HKD | -2.58B HKD | -387.8M HKD |
Detailed financial statements for XtalPi
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XtalPi
XtalPi has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Liverpool ChiroChem.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small organic molecules are supplied for biotech and pharmaceutical R&D. | liverpoolchirochem.com | Liverpool, United Kingdom | 2014 | Jun 2025 | •••• |
Complete acquisition details for XtalPi
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of XtalPi
6 dated milestones of XtalPi across 11 years, from founding to its latest funding, stage changes and deals.
- Founded XtalPi is founded.
- Funding First funding round of $3.7M.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Liverpool ChiroChem.
- Funding Latest funding round, Post-IPO, of $268.0M.
Competitors of XtalPi
XtalPi has 3 listed competitors in our database, 3 of them funded. They include Formation Bio, BigHat and Predictive Oncology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| formation.bio | 2016 | New York, United States | $608.25M | AI-powered drug discovery platform for various diseases | ||
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | Antibody therapies are developed through machine learning and synthetic biology. | ||
| predictive-oncology.com | 2002 | Eagan, United States | $43M | 31 | AI-based platform for cancer diagnostics and precision medicine is utilized. |
Detailed competitors of XtalPi
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of XtalPi
The website of XtalPi (xtalpi.com) receives about 27.6K visits a month.
- Monthly visits27.6K
▲ 3.2% vs previous month
Websites whose visitors overlap most with XtalPi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| drughunter.com | 100% | 52.6K | #647,163 | View details | |
| hkstp.org | 60% | #162,888 | View details | ||
genscript.com.cn | genscript.com.cn | 60% | #370,616 | – | |
moleculardevices.com.cn | moleculardevices.com.cn | 60% | #3,058,865 | – |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as XtalPi (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xtalpi
Complete news archive for XtalPi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XtalPi
XtalPi was founded in 2014 and raised its 1st funding round 1 year after it was founded.
XtalPi is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
XtalPi is a funded company, having raised a total of $784.8M across 7 funding rounds to date. The company's 1st funding round was a Series A of $3.7M, raised on Jun 2015.
XtalPi has 393 employees.
Annual revenue of XtalPi is $111.82M as on Dec 31, 2025.
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The companys algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
XtalPi's top competitors include Formation Bio, Predictive Oncology and BigHat.
Yes, XtalPi is publicly traded on HKEX under the ticker symbol 2228.
XtalPi has made 1 acquisition, including Liverpool ChiroChem.
XtalPi has 26 investors. Key investors include Google, Tencent, Mirae Asset, CICC, and Renren.
The valuation of XtalPi is $2.01B as of Aug 2021.
XtalPi operates through Xtalpi Inc.